ArticlePaediatric and perinatal epidemiology2026
Safety of Antihypertensive Medication for the Management of Non-Severe Gestational Hypertension Among Pregnant Individuals in Botswana-Emulating a Series of Target Trials.
Article in Paediatric and perinatal epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundData on antihypertensive medication for non-severe gestational hypertension may suffer from immortal time and selection bias. Emulating target trials can prevent these biases by aligning follow-up with treatment initiation.
objectivesWe estimated the safety of antihypertensive medication initiation for the treatment of non-severe gestational hypertension on adverse birth outcomes in Botswana using sequential target trial emulation.
methodsData from the Tsepamo study (2014-2022), capturing birth outcomes at government delivery sites in Botswana, was used to examine antihypertensive medication initiation ≥ 24 weeks gestation for non-severe gestational hypertension (140-159 systolic or 90-109 diastolic blood pressure ≥ 20 weeks gestation without chronic hypertension). Sequential weekly target trial emulation compared initiation versus no initiation during 24-35 weeks' gestation on the risk of stillbirth and birth of infant small for gestational age (SGA), with secondary outcomes including very SGA, preterm birth, very preterm birth, neonatal death, and severe gestational hypertension. For each trial, eligible individuals were without chronic hypertension, had not previously initiated antihypertensive medication and had ≥ 2 non-severe blood pressure readings, at least one within 1 week of trial start. Log-binomial models estimated gestational week-specific and pooled risk ratios (RR) with 95% confidence intervals (CI) using bootstrapping.
resultsOf eligible individuals, there were 1676 antihypertensive initiator 'person-trials' and 5211 non-initiator 'person-trials'. In the pooled analysis, the adjusted RR for stillbirth and SGA comparing initiators to non-initiators was 0.92 (0.68, 1.19) and 1.09 (0.97, 1.23), respectively. The pooled adjusted RR for secondary outcomes were: very SGA, 1.05 (95% CI 0.88, 1.25); preterm birth, 1.09 (95% CI 0.96, 1.22); very preterm birth, 1.05 (95% CI 0.78, 1.47); neonatal death, 1.23 (95% CI 0.68, 2.24); severe gestational hypertension, 0.88 (95% CI 0.74, 1.07).
conclusionsIn this retrospective cohort study, antihypertensive medication initiation between 24 and 35 weeks' gestation for non-severe gestational hypertension was not associated with increased risk of adverse birth outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.